Glucuronidation of fimasartan, a new angiotensin receptor antagonist, is mainly mediated by UGT1A3

References

• Alonen A, Finel M, Kostiainen R. (2008). The human UDP-glucuronosyltransferase UGT1A3 is highly selective towards N2 in the tetrazole ring of losartan, candesartan, and zolarsartan. Biochem Pharmacol 76:763–72
   PubMed Web of Science ®Google Scholar
• Chi YH, Lee H, Paik SH, et al. (2011). Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects. Am J Cardiovasc Drugs 11:335–46
   PubMed Web of Science ®Google Scholar
• Court MH. (2005). Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases. Methods Enzymol 400:104–16
   PubMed Web of Science ®Google Scholar
• Crespi CL. (1995). Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. Advances in drug research. New York: Academic Press, 179–235
   Google Scholar
• Di Marco A, D’Antoni M, Attaccalite S, et al. (2005). Determination of drug glucuronidaion and UDP-glucuronosyltransferase selectivity using a 96-well radiometric assay. Drug Metab Dispos 33:812–19
   PubMed Web of Science ®Google Scholar
• Donato MT, Montero S, Castell JV, et al. (2010). Validated assay for studying activity profiles of human liver UGTs after drug exposure: inhibition and induction studies. Anal Bioanal Chem 396:2251–63
   PubMed Web of Science ®Google Scholar
• Fallon JK, Neubert H, Goosen TC, Smith PC. (2013a). Targeted precise quantification of 12 human recombinant uridine-diphosphate glucuronosyl transferase 1A and 2B isoforms using nano-ultra-high-performance liquid chromatography/tandem mass spectrometry with selected reaction monitoring. Drug Metab Dispos 41:2076–80
   PubMed Web of Science ®Google Scholar
• Fallon JK, Neubert H, Hyland R, et al. (2013b). Targeted quantitative proteomics for the analysis of 14 UGT1As and -2Bs in human liver using NanoUPLC-MS/MS with selected reaction monitoring. J Proteome Res 12:4402–13
   PubMed Web of Science ®Google Scholar
• Fujiwara R, Nakajima M, Yamanaka H, et al. (2007a). Interactions between human UGT1A1, UGT1A4, and UGT1A6 affect their enzymatic activities. Drug Metab Dispos 35:1781–7
   PubMed Web of Science ®Google Scholar
• Fujiwara R, Nakajima M, Yamanaka H, et al. (2007b). Effects of coexpression of UGT1A9 on enzymatic activities of human UGT1A isoforms. Drug Metab Dispos 35:747–57
   PubMed Web of Science ®Google Scholar
• Gu N, Kim B, Lim KS, et al. (2012). The effect of fimasartan, an angiotensin receptor type 1 blocker, on the pharmacokinetics and pharmacodynamics of warfarin in healthy Korean male volunteers: a one-sequence, two-period crossover clinical trial. Clin Ther 34:1592–600
   PubMed Web of Science ®Google Scholar
• Huskey SE, Miller RR, Chiu SH. (1993). N-glucuronidation reactions. I. tetrazole N-glucuronidation of selected angiotensin II receptor antagonists in hepatic microsomes from rats, dogs, monkeys, and humans. Drug Metab Dispos 21:792–99
   PubMed Web of Science ®Google Scholar
• Kim JH, Lee JH, Paik SH, et al. (2012). Fimasartan, a novel angiotensin II receptor antagonist. Arch Pharm Res 35:1123–6
   PubMed Web of Science ®Google Scholar
• Kim JW, Yi S, Kim TE, et al. (2013). Increased systemic exposure of fimasartan, an angiotensin II receptor antagonist, by ketoconazole and rifampicin. J Clin Pharmacol 53:75–81
   PubMed Web of Science ®Google Scholar
• Kim TH, Shin S, Bashir M, et al. (2014). Pharmacokinetics and metabolite profiling of fimasartan, a novel antihypertensive agent, in rats. Xenobiotica. [Epub ahead of print]. doi: 10.3109/00498254.2014.915359
   Google Scholar
• King CD, Rios GR, Green MD, Tephly TR. (2000). UDP-glucuronosyltransferases. Curr Drug Metab 1:143–61
   PubMed Web of Science ®Google Scholar
• Lane A, Kleinermanns D, Brysone S, et al. (2005). Multiple dose pharmacokinetics (PK) and pharmacodynamics (PD) of BR-A-657, an angiotensinII (AII) antagonist. Clin Pharmacol Ther 77:58–8
   Google Scholar
• Lee HW, Lim MS, Seong SJ, et al. (2011). Effect of age on the pharmacokinetics of fimasartan (BR-A-657). Expert Opin Drug Metab Toxicol 7:1337–44
   PubMed Web of Science ®Google Scholar
• Liston HL, Markowitz JS, DeVane CL. (2001). Drug glucuronidation in clinical psychopharmacology. J Clin Psychopharmacol 21:500–15
   PubMed Web of Science ®Google Scholar
• Mackenzie PI, Owens IS, Burchell B, et al. (1997). The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 7:255–69
   PubMedGoogle Scholar
• Miners JO, Mackenzie PI, Knights KM. (2010). The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro–in vivo extrapolation of drug clearance and drug–drug interaction potential. Drug Metab Rev 42:196–208
   PubMed Web of Science ®Google Scholar
• Riedmaier S, Klein K, Hofmann U, et al. (2010). UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo. Clin Pharmacol Ther 87:65–73
   PubMed Web of Science ®Google Scholar
• Shin JG, Soukhova N, Flockhart DA. (1999). Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos 27:1078–84
   PubMed Web of Science ®Google Scholar
• Shin BS, Kim TH, Paik SH, et al. (2011a). Simultaneous determination of fimasartan, a novel antihypertensive agent, and its active metabolite in rat plasma by liquid chromatography-tandem mass spectrometry. Biomed Chromatogr 25:1208–14
   Google Scholar
• Shin KH, Kim TE, Kim SE, et al. (2011b). The effect of the newly developed angiotensin receptor II antagonist fimasartan on the pharmacokinetics of atorvastatin in relation to OATP1B1 in healthy male volunteers. J Cardiovasc Pharmacol 58:492–9
   PubMed Web of Science ®Google Scholar
• Stevens JC, Fayer JL, Cassidy KC. (2001). Characterization of 2-[[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]methoxy]phenoxy]methyl] quinoline N-glucuronidation by in vitro and in vivo approaches. Drug Metab Dispos 29:289–95
   PubMed Web of Science ®Google Scholar
• Trottier J, Verreault M, Grepper S, et al. (2006). Human UDP-glucuronosyltransferase (UGT)1A3 enzyme conjugates chenodeoxycholic acid in the liver. Hepatology 44:1158–70
   PubMed Web of Science ®Google Scholar
• Tukey RH, Strassburg CP. (2000). Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581–616
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, von Moltke LL, Court MH, et al. (2000). Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab Dispos 28:1493–504
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Nakajima M, Ohashi N, et al. (2003). Glucuronidation of etoposide in human liver microsomes is specifically catalyzed by UDP-glucuronosyltransferase 1A1. Drug Metab Dispos 31:589–95
   PubMed Web of Science ®Google Scholar
• Williams JA, Ring BJ, Cantrell VE, et al. (2002). Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes. Drug Metab Dispos 30:1266–73
   PubMed Web of Science ®Google Scholar
• Yamada A, Maeda K, Ishiguro N, et al. (2011). The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers. Pharmacogenet Genomics 21:523–30
   PubMed Web of Science ®Google Scholar